Renaissance Technologies LLC grew its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 65.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,654 shares of the company's stock after buying an additional 45,200 shares during the period. Renaissance Technologies LLC owned 0.20% of Ginkgo Bioworks worth $1,126,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in Ginkgo Bioworks in the 4th quarter valued at about $29,000. KBC Group NV bought a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $31,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Ginkgo Bioworks during the 4th quarter valued at approximately $46,000. Palumbo Wealth Management LLC bought a new position in Ginkgo Bioworks in the 4th quarter worth approximately $144,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Ginkgo Bioworks in the 4th quarter valued at approximately $154,000. Institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Price Performance
Shares of NYSE:DNA traded down $0.18 during trading on Monday, hitting $6.86. 123,106 shares of the company were exchanged, compared to its average volume of 1,576,499. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $41.20. The stock has a 50 day moving average of $7.24 and a 200 day moving average of $9.14. The company has a market cap of $398.17 million, a PE ratio of -0.52 and a beta of 1.34.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
